Status | Study |
Recruiting |
Study Name: A Study of the Safety and Efficacy of EBV Specific T-cell Lines Condition: Epstein-Barr Virus Infections Post-Transplant Lymphoproliferati Date: 2015-10-15 Interventions: Biological: Group A Peptide-st |
Recruiting |
Study Name: Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients Condition: Lymphoproliferative Disorders Date: 2015-07-15 Interventions: Other: Determining the source of EBV in severe EBV infections Blood units administered to patients with |
Recruiting |
Study Name: Mental Training for CFS Following EBV Infection in Adolescents Condition: Fatigue Syndrome, Chronic Epstein-Barr Virus Infection Date: 2015-07-09 Interventions: Behavioral: Mental training |
Active, not recruiting |
Study Name: Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents Condition: Fatigue Syndrome, Chronic Epstein-Barr Virus Infections Date: 2015-01-07 |
Recruiting |
Study Name: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA Condition: Epstein-Barr Virus Infection Stage II Nasopharyngeal Carcinoma Date: 2014-05-07 Interventions: Drug: Cisplatin Given IV |
Recruiting |
Study Name: ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation Condition: Transplantation Infection Epstein-Barr Virus Infections Date: 2013-10-10 Interventions: Drug: Valacyclovir Experimenta |
No longer available |
Study Name: Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH) Condition: EBV Infection CMV Infection A Date: 2013-09-16 Interventions: Biological: Trivirus-Specific CTLs Patients will receive up to 2 x 10^7 CHM-CTL/m2 as a single infusion |
Active, not recruiting |
Study Name: A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma Condition: Nasopharyngeal Cancer Epstein Barr Virus Infections Date: 2013-02-25 Interventions: Drug: MVA-EBNA1/LMP2 vaccine |
Recruiting |
Study Name: Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against Epstein Barr Virus, Adenovirus, And Cytomegalovirus Condition: Epstein-Barr Virus Infections Adenovirus Date: 2012-02-06 Interventions: Biological: Cytotoxic T Lymphocytes Patients will be studied in cohorts of 3. Eligible patients will rec |
Completed |
Study Name: Modified Vaccinia Ankara (MVA) Vaccine Study Condition: Nasopharyngeal Neoplasms Epstein-Barr Virus Infections Date: 2010-12-08 Interventions: Drug: MVA Vaccine The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vacc |